Leukemia: Difference between revisions

From IDWiki
(restructured)
()
 
Line 1: Line 1:
== Clinical Manifestations ==
+
==Clinical Manifestations==
   
*Often cytopenia-related symptoms
+
*Often cytopenia-related symptoms, including [[anemia]], [[leukopenia]], and [[thrombocytopenia]]
  +
*May also present with [[DIC]], [[tumour lysis syndrome]], or [[leukostasis]]
   
 
==Differential Diagnosis==
 
==Differential Diagnosis==
Line 24: Line 25:
 
*Rule out [[DIC]] (especially seen in [[APL]])
 
*Rule out [[DIC]] (especially seen in [[APL]])
   
==== [[Tumour lysis syndrome]] ====
+
====[[Tumour lysis syndrome]]====
   
 
*2 or more: [[hyperkalemia]], [[hyperphosphatemia]], [[hypocalcemia]], [[hyperuricemia]]
 
*2 or more: [[hyperkalemia]], [[hyperphosphatemia]], [[hypocalcemia]], [[hyperuricemia]]
Line 33: Line 34:
 
*Do NOT treat [[hypocalcemia]]
 
*Do NOT treat [[hypocalcemia]]
   
==== [[Leukostasis]] ====
+
====[[Leukostasis]]====
   
 
*More common in [[AML]] than any other
 
*More common in [[AML]] than any other
Line 43: Line 44:
 
**No evidence for [[leukopheresis]]
 
**No evidence for [[leukopheresis]]
   
==== Suspected [[APL]] ====
+
====Suspected [[APL]]====
   
 
*Consult Hematology overnight
 
*Consult Hematology overnight
Line 57: Line 58:
 
===Chronic===
 
===Chronic===
   
==== AML ====
+
====AML====
   
 
*Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient
 
*Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient
Line 64: Line 65:
 
**High/poor risk: 1-2 more cycles, then alloSCT
 
**High/poor risk: 1-2 more cycles, then alloSCT
   
==== APL ====
+
====APL====
   
 
*ATRA + arsenic trioxide
 
*ATRA + arsenic trioxide
   
==== ALL ====
+
====ALL====
   
 
*Dana-Farber protocol
 
*Dana-Farber protocol

Latest revision as of 11:47, 30 July 2020

Clinical Manifestations

Differential Diagnosis

  • Primary: suspect when multiple lineages affected, significant leukocytosis, lymphadenopathy, splenomegaly
  • Secondary
    • Acute infection (30-50%)
    • Chronic inflammation
    • Stress (MI, surgery, burn) (30-50%)
    • Steroids
    • Pregnancy
    • Cigarette smoking

Investigations

  • Urgent blood film review to r/o APL

Management

Acute

  • Rule out DIC (especially seen in APL)

Tumour lysis syndrome

Leukostasis

  • More common in AML than any other
  • Lungs and brain most commonly affected
  • Cytoreduction
    • Induction chemotherapy as soon as possilble
    • Overnight, give hydroxyurea 2g q6h
      • Can develop tumour lysis syndrome
    • No evidence for leukopheresis

Suspected APL

  • Consult Hematology overnight
  • Start ATRA 45mg/m2 divided BID
  • Beware differentiation syndrome, with fever, effusion, dyspnea, hypotension; treated with steroids
  • Beware DIC

Chronic

AML

  • Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient
  • BM to confirm induction, then consolidation
    • Low risk: 2-3 more cycles of same
    • High/poor risk: 1-2 more cycles, then alloSCT

APL

  • ATRA + arsenic trioxide

ALL

  • Dana-Farber protocol
  • 2+ years of chemo + steroids
  • For Philadelphia positive disease, add imatinib